A systematic review and meta-analysis of seven studies (five open-label and two randomized controlled trials) found that a single 25 mg dose of psilocybin per clinical session is effective for treatment-resistant depression. The 25 mg dose significantly reduced depressive severity compared to 10 mg and 1 mg doses, with two-dose studies showing greater benefit than single-dose studies. The evidence suggests psilocybin is a promising therapeutic, though more research is needed due to limitations in the available studies.
A growing number of novel psychoactive substances (NPS) are entering circulation, yet their pharmacological profiles and risks are often unknown. To aid prediction of properties for uncharacterized analogues, a chemical inventory of 690 distinct NPS with defined structures was compiled from governmental and analytical reports, supplemented by 155 established psychoactive drugs of abuse (EPDA). Classification by molecular features, subjective effects, and pharmacological mechanisms identified over forty chemical groupings, seven effect categories, and six mechanisms. Co-occurrence of NPS and EPDA within classes was common, highlighting potential for chemical read-across and derivation of structural alerts.